Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging.

PURPOSE To evaluate the ability of dynamic contrast material-enhanced and diffusion-weighted (DW) magnetic resonance (MR) imaging to help detect early response to chemotherapy in patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS This study was approved by the institutional review board, and written informed consent was obtained from all subjects. Twenty-eight patients with stage IIIB or IV NSCLC (17 women, 11 men; mean age, 64.8 years) who underwent chemotherapy were enrolled. All patients underwent MR imaging before and after the first course of chemotherapy. The time to peak enhancement, maximum enhancement ratio, and washout ratio were determined from the time-signal intensity curves of dynamic contrast-enhanced MR images. The apparent diffusion coefficient (ADC) of each lung carcinoma was calculated from DW MR images. The responses of these parameters to the first course of chemotherapy and the pretreatment ADC itself were compared with final tumor size reduction by using the Pearson correlation coefficient. Kaplan-Meier curves of progression-free survival and overall survival were generated, and comparisons between the group with a good response of the significant parameter (upper 50th percentile) and that with a poor response of the significant parameter (lower 50th percentile) were performed by using a two-sided log-rank test. RESULTS Significant correlation was found only between early ADC change and final tumor size reduction rate (r(2) = 0.41, P = .00025). The median progression-free survival for the group with a good increase in ADC was 12.1 months, and that for the group with a stable or decreased ADC was 6.67 months (P = .021), while median overall survival was 22.4 and 12.3 months, respectively (P = .048). CONCLUSION ADC seems to be a promising tool for monitoring the early response to or predicting prognosis after chemotherapy of NSCLC.

[1]  J. M. Taylor,et al.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.

[2]  L. Shen,et al.  Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. , 2008, Radiology.

[3]  G. Weinstein,et al.  Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting Early Response to Chemoradiation Therapy of Squamous Cell Carcinomas of the Head and Neck , 2009, Clinical Cancer Research.

[4]  S. Gautam,et al.  Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings. , 2010, Radiology.

[5]  Danny Rischin,et al.  Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Bernd Hamm,et al.  Diffusion‐weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft‐tissue sarcomas , 2008, Journal of magnetic resonance imaging : JMRI.

[7]  Hyae-Young Kim,et al.  Early Prediction of Response to First-Line Therapy Using Integrated 18F-FDG PET/CT for Patients with Advanced/Metastatic Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  M. Matoba,et al.  Lung carcinoma: diffusion-weighted mr imaging--preliminary evaluation with apparent diffusion coefficient. , 2007, Radiology.

[9]  Brian D Ross,et al.  Predicting and monitoring cancer treatment response with diffusion‐weighted MRI , 2010, Journal of magnetic resonance imaging : JMRI.

[10]  Bradford A Moffat,et al.  Prospective Early Response Imaging Biomarker for Neoadjuvant Breast Cancer Chemotherapy , 2007, Clinical Cancer Research.

[11]  Ning Wu,et al.  Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. , 2009, AJR. American journal of roentgenology.

[12]  Y. Kitazume,et al.  Can malignant and benign pulmonary nodules be differentiated with diffusion-weighted MRI? , 2008, AJR. American journal of roentgenology.

[13]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Hidetake Yabuuchi,et al.  Index terms: , 2002 .

[15]  W. Oyen,et al.  Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer , 2007, Journal of Nuclear Medicine.

[16]  Jürgen Griebel,et al.  Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. , 2003, International journal of radiation oncology, biology, physics.

[17]  F. Gilbert,et al.  Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. , 2008, Gynecologic oncology.

[18]  S. Matsumoto,et al.  Prognostic value of dynamic MR imaging for non‐small‐cell lung cancer patients after chemoradiotherapy , 2005, Journal of magnetic resonance imaging : JMRI.

[19]  S. Shiraishi,et al.  Diffusion-Weighted Magnetic Resonance Imaging for Diagnosing Malignant Pulmonary Nodules/Masses: Comparison with Positron Emission Tomography , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  T L Chenevert,et al.  Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Thomas E Yankeelov,et al.  Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. , 2007, Magnetic resonance imaging.